References
- Zhilinskaya NT, Bespalov VG, Semenov AL, et al. Cisplatin effect on digital cytomorphometric and bioinformatic tumor cell characteristics in rat ovarian cancer model-a preliminary study. Pharmacol Rep. 2021;73(2):642–649.
- Yang XY, Li Y, Cai SQ, et al. Optimization of 7,12-dimethylbenz(a)anthracene-induced rat epithelial ovarian tumors. Oncol Lett. 2021;21(3):206.
- Matsuo K, Lin YG, Roman LD, et al. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010;19(11):1339–1354.
- Roy D, Sheng GY, Herve S, et al. Interplay between cancer cell cycle and metabolism: challenges, targets and therapeutic opportunities. Biomed Pharmacother. 2017;89:288–296.
- Gill RM, Gabor TV, Couzens AL, et al. The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation. Mol Cell Biol. 2013;33(3):498–513.
- Jiménez-P R, Martín-Cortázar C, Kourani O, et al. CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth. Haematologica. 2018;103(10):1669–1678.
- Osthus RC, Karim B, Prescott JE, et al. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res. 2005;65(13):5620–5627.
- Li S, Huang J, Qin M, et al. High expression of CDCA7 predicts tumor progression and poor prognosis in human colorectal cancer. Mol Med Rep. 2020;22(1):57–66.
- Cho H, Lim BJ, Kang ES, et al. Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med. 2009;218(2):129–139.
- Irshad R, Husain M. Natural products in the reprogramming of Cancer epigenetics. Toxicol Appl Pharmacol. 2021;417:115467.
- Gentile C, Kmita M. Polycomb repressive complexes in hox gene regulation: silencing and beyond: the functional dynamics of polycomb repressive complexes in hox gene regulation. Bioessays. 2020;42(10):e1900249.
- Aoyama K, Shinoda D, Suzuki E, et al. PRC2 insufficiency causes p53-dependent dyserythropoiesis in myelodysplastic syndrome. Leukemia. 2020;35(4):1156-1165.
- Liang W, Wu J, Qiu X. LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting EZH2-regulated TPM1. J Transl Med. 2021;19(1):45.
- Dai ZY, Jin SM, Luo HQ, et al. LncRNA HOTAIR regulates anoikis-resistance capacity and spheroid formation of ovarian cancer cells by recruiting EZH2 and influencing H3K27 methylation. Neoplasma. 2021;68(3):509–518.
- Santoni M, Miccini F, Cimadamore A, et al. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opin Investig Drugs. 2021;30(3):245-251.
- Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156.
- Cabral-Pacheco GA, Garza-Veloz I, Castruita-de La Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739.
- Scheau C, Badarau IA, Costache R, et al. The role of matrix metalloproteinases in the Epithelial-Mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol (Amst). 2019;2019:9423907.
- Ntellas P, Mavroeidis L, Gkoura S, et al. Old player-new tricks: non angiogenic effects of the VEGF/VEGFR pathway in cancer. Cancers (Basel). 2020;12(11):3145.
- Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.
- Rinderknecht M, Villa A, Ballmer-Hofer K, et al. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS One. 2010;5(8):e11941.
- Su SG, Li QL, Zhang MF, et al. An E2F1/DDX11/EZH2 positive feedback loop promotes cell proliferation in hepatocellular carcinoma. Front Oncol. 2020;10:593293.
- Sun XB, Chen YW, Yao QS, et al. MicroRNA-144 suppresses prostate cancer growth and metastasis by targeting EZH2. Technol Cancer Res Treat. 2021;20:1533033821989817.
- Yang X, Wang J, Li H, et al. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway. Int J Mol Med. 2021;47(2):668–676.
- Zong X, Wang W, Ozes A, et al. EZH2-Mediated downregulation of the tumor suppressor DAB2IP maintains ovarian cancer stem cells. Cancer Res. 2020;80(20):4371–4385.